Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;101(10):2289-2296.
doi: 10.1007/s00277-022-04953-1. Epub 2022 Aug 24.

Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH

Guangqiang Meng  1 , Jingshi Wang  1 , Tingting Cui  1 , Zhao Wang  2
Affiliations

Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH

Guangqiang Meng et al. Ann Hematol. 2022 Oct.

Abstract

Natural killer (NK)/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis (NK/T-LAHLH) is a rare and life-threatening disorder. Its clinical characteristics and appropriate treatment options are unclear. This study aimed to investigate the clinical characteristics and treatment options for this disease. We retrospectively analyzed the clinical data of 84 patients with NK/T-cell lymphoma and compared the characteristics, treatment, and survival between patients with and without HLH. Patients in the NK/T-LAHLH group were more likely to be younger age and have hepatosplenomegaly, B symptoms, neutropenia, anemia, thrombocytopenia, elevated lactate dehydrogenase levels, reduced serum albumin levels, bone marrow involvement, Ann Arbor stage III/IV, and International Prognostic Index score ≥ 3. After multivariate analysis, it was found that elevated lactate dehydrogenase and Ann Arbor stage III/IV were risk factors for HLH in patients with NK/T-cell lymphoma. After 2 weeks of therapy, 78.6% (11/14) patients who received the L-DEP/DEP regimen achieved an overall response rate of HLH, which was higher than that in 42.9% (9/21) patients who received the VP-16 + dexamethasone-based regimen. NK/T-LAHLH patients had poorer survival than non-HLH-NK/TCL patients. For NK/T-LAHLH, the L-DEP/DEP regimen may have a better response rate than the VP-16 + dexamethasone-based regimens.

Keywords: Hemophagocytic lymphohistiocytosis; NK; T-cell lymphoma; Treatment.

PubMed Disclaimer

References

    1. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131 - DOI
    1. Skinner J, Yankey B, Shelton BK (2019) Hemophagocytic lymphohistiocytosis. AACN Adv. Crit Care 30(2):151–164
    1. Rivière S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, Fardet L (2014) Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med 127(11):1118–1125 - DOI
    1. Lehmberg K, Nichols KE, Henter JI, Girschikofsky M, Greenwood T, Jordan M, Kumar A, Minkov M, La Rosée P, Weitzman S, Study Group on HemophagocyticLymphohistiocytosis Subtypes of the Histiocyte Society (2015) Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica 100(8):997–1004 - PubMed - PMC
    1. Fugl A, Andersen CL (2019) Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam Pract 20(1):62 - DOI

MeSH terms

LinkOut - more resources